NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Vesalius Therapeutics

Vesalius Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.vesaliustx.com/

Last Round

Strategic

Nov 12, 2024

Total Funding Raised

$155M

Company Overview

Vesalius Therapeutics is a biotechnology company that develops a drug discovery platform to identify genetic circuits driving common illnesses and create patient-derived models for screening drug candidates.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

precision medicinedrug discoverybiotech startupAI drug discoveryDIAMOND platformcomputational biologypatient stratificationtherapeutic target identificationin silico drug discoverybiotech R&Dgenetic disease researchpharma partnershipFlagship Pioneeringclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vesalius Therapeutics Comparables

Compare Vesalius Therapeutics with similar companies based on industry and business-model similarity.

Vesalius Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Empress Therapeutics
84%
Quotient Therapeutics
83%
PrecisionLife
82%

Vesalius Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicNov 12, 2024
Series AMar 2, 2022

Key People

Founding team and executive leadership

Yasir Al-Wakeel

Chief Executive Officer

Executive Team

Vesalius Therapeutics Investors

Notable investors and investment history

Vesalius Therapeutics investors
InvestorRounds
Flagship PioneeringSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 2, 2022

    $75M Series A round completed.

Vesalius Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Vesalius Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Vesalius Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range32
Year Founded2019
Last FundingNov 12, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.